1FW

AUG 0 7 2006 %

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(Case No.: 02-728-L (400/166US))

In the Application of:

McSwiggen, et al.

Serial No.: 10/562,561

Filed:

December 27, 2005

For: RNA Interference Mediated Treatment of Alzheimer's Disease Using Short Interfering Nucleic Acid (siNA) Art Unit: TBA

Examiner: Not assigned

Conf. No. 3830

TRANSMITTAL LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In regard to the above-identified application:

- 1. We are transmitting herewith the attached
 - a. PTO Form 1449;
 - b. Two (2) cited references; and
 - c Return Receipt Postcard
- 2. It is believed no fee is due at this time. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.

3. CERTIFICATE OF MAILING UNDER 37 CFR §1.8: The undersigned hereby certifies that this Transmittal Letter and the paper described in paragraph 1, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on August 2, 2006.

Respectfully submitted,

Date: August 2, 2006

By:

Lisa M.W. Hillman, Ph.D

Reg. No. 43,673

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE the Panerwork Reduction Apt of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number 10/562,561 December 27, 2005 Filing Date McSwiggen First Named Inventor TBA Art Unit **Examiner Name** TBA 02-728-L (400.166US)

(Use as many sheets as necessary) Attorney Docket Number Sheet

			U. S. PATENT	DOCUMENTS	Line Minero
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
muais	140.	Number-Kind Code ^{2 (if known)}	10.0000	Dobie	· · · · · · · · · · · · · · · · · · ·
	*	us- 2003/0232435	12-2003		
	*	us- 5,998,203	12-1999	Matulic-Adamic	
	*	us-6,046,320	04-2000	Monia et al.	
	*	us-2002/0151693	10-2002	Breaker et al.	
		US-			
	1	US-			
		US-			
		US-	<u> </u>		
		US-			
		US-			
		US-	<u> </u>		
		US	ļ		
		US	<u> </u>		
		US-	<u> </u>		
		US-			
		US			
		US-			
		US- 3"			

	_	FOREIGN	ATENT DOCL	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages T or Relevant Figures Appear
	ļ.—-	Country Code ³ "Number ⁴ "Kind Code ⁵ (if known) WO 94/01550	01-1994	Agrawal et al.	
	 	VVO 94/01030			
	┼				ļ
	┼				
	<u> </u>		 		

Ì			
Į		Date	
۱	Examiner Signature	Considered	for any pot
١	Signature	 Constitution of the second sec	citation if not in conformance and not

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, uspection of the process of the on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Apt of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

	Complete if Known		
Substitute for form 1449B/PTO	Application Number	10/562,561	
INFORMATION DISCLOSURE	Filing Date	December 27, 2005	
STATEMENT BY APPLICANT	First Named Inventor	McSwiggen	
STATEMENT DIVILLE	Art Unit	TBA	
(Use as many sheets as necessary)	Examiner Name	ТВА	
Sheet 2 of 2	Attorney Docket Number	02-728-L	

		NON PATENT LITERATURE DOCUMENTS	
Examiner nitials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Shaw et al., (1991) Nucleic Acids Res. 19:747-750	
		Snaw et al., (1991) Nucleic Midd Med	
	*	Chang et al., (1999) J. Mol. Neuroscience 12:69-74	+-
	1	GenBank Accession No. CQ989002, January 25, 2005	╄-
	-}'	Genbank / Roccosion - No. 12 - 12 - 12 - 12 - 12 - 12 - 12 - 12	ļ
		21 2000	
2 GenBank Accession No. NM_000484 October 31, 2000 Schmidt et al., "Bases and sugar requirements for RNA cleavage of essential			1
		residues in internal loop B of the hairpin ribozyme: Internal loop B of the loop B	
* Nucleic Acids Research, 1996, Vol. 24, No. 4:573-581			
		Caplen NJ, "RNAi as a Gene Therapy Approach", Expert Opinion Biol. Thera. (2003) Vol.	
	-	3(4):575-586	
		Hammond et al., "Post-transcriptional gene silencing by double-stranded RNA" Nature,	
	*	2001, Vol. 2, 110-119	+-
	-+		
			\top
			上
	1		

Examiner Signature	Date Considered	
Signature		ab citation if not in conformance and not

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation it not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, uspectively including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Commissioner for Patents. P.O. Box 1450, Alexandria, VA 22313-1450. ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.